Blue Cross Blue Shield/Blue Care Network of Michigan Medication Authorization Request Form



Nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association

This form is to be used by participating physicians to obtain coverage for **drugs covered under the medical benefit**. For commercial members only, please complete this form and submit via fax to 1-877-325-5979. If you have any questions regarding this process, please contact BCBSM Provider Relations and Servicing or the Medical Drug Helpdesk at

1-800-437-3803	for assistance.	
PATIENT INFORMATION		PHYSICIAN INFORMATION
Name		Name
ID Number Spec		Specialty
D.O.B. / MM/DD/YYYY Add		Address
		City /State/Zip
Drug Name AMVUTTRA Phone Fax:		Phone:
Dose and Quantity NPI		
Directions Con-		Contact Person
Date of Service(s) Conta / Ext.		Contact Person Phone
STEP 1: DISEASE STATE INFORMATION		
Required Demographic Information:		
Patient Weight: kg		
	Patient Height: ft inches	
Will the provider be administering the medication to the FEP member within the health plan's geographic service area? Yes No \text{If No, a prior authorization is not required through this process.}		
Prior authorizations are required for FEP members that will be serviced by a provider within the health plan's geographic service area. If you are not a provider in the geographic service area, please contact the health plan for questions regarding the FEP member's benefit requirements.		
Is this member's FEP coverage primary or secondary coverage? ☐ If primary, continue with questionset. ☐ If secondary, an authorization is not needed through this process. Please contact the member's primary coverage for determination of benefit and additional information.		
Criteria Questions: 1. Does the patient have a diagnosis of Polyneuropathy of Hereditary Transthyretin-mediated (hATTR) □Yes □No		
 2. Does the prescriber agree to supplement the patient with the recommended daily allowance of Vitamin A if indicated? □Yes □No 		
3. Will Amvuttra be used in combination with another medication for polyneuropathy caused by hATTR amyloidosis? □Yes □No		
*If YES, please specify medication:		
4. Has the patient been on Amvuttra continuously for the last 6 months, excluding samples? Please select answer below:		
□ NO – this is INITIATION of therapy, please answer the following questions: a. Has the patient's diagnosis been confirmed by genetic testing or tissue biopsy showing amyloid deposition? □Yes □No b. Does the patient have a baseline score using the polyneuropathy disability (PND) scoring tool less than or equal to Stage IIIb? □Yes		
*If NO, does the patient have a baseline score of Stage 1 or 2 using the FAP scoring tool? □Yes □No c. Does the patient have New York Heart Association (NYHA) class 3 or 4 heat failure? □Yes □No d. Does the patient have a sensorimotor or autonomic neuropathy not related to hATTR amyloidosis (monoclonal gammopathy, autoimmune disease, etc.)? □Yes □No		
e. Has the patient had a prior liver transplantation? □Yes □No f. Is Amvuttra being prescribed by or in consultation with a neurologist, or a specialist in the treatment of the patient's diagnosis? □Yes □No		
□ YES – this is a PA renewal for CONTINUATION of therapy, please answer the following question: a. Has the patient's condition improved or stabilized with Amvuttra? □ Yes □ No		
Chart notes are required for the processing of all requests. Please add any other supporting medical information necessary for our review (required) Coverage will not be provided if the prescribing physician's signature and date are not reflected on this document.		
Request for expedited review: I certify that applying the standard review time frame may seriously jeopardize the life or health of the member or the member's ability to regain maximum function		
Physician's N		Date
Step 2: Checklist	☐ Form Completely Filled Out ☐ Provide chart notes	☐ Attach test results
Step 3: Submit	By Fax: BCBSM Specialty Pharmacy Mailbox 1-877-325-5979	By Mail: BCBSM Specialty Pharmacy Program P.O. Box 312320, Detroit, MI 48231-2320